"A lot of shared decision-making has to do with, what is important to the individual man?" says Dean S. Elterman, MD, MSc, FRCSC. In this interview, Dean S. Elterman, MD, MSc, FRCSC, gives an overview ...

"My second book is on pelvic pain or prostatitis. It is focused on a holistic approach and stretches and mindfulness exercises," says Vanita Gaglani, RPT. In this video, Vanita Gaglani, RPT, discusses ...

ctDNA in metastatic RCC shows high concordance with disease progression and indolence in negative cases, indicating its prognostic value. A clinical trial is underway to explore treatment ...

The Revi System showed sustained efficacy at 24 months, with 79% of patients responding to therapy and significant reductions in UUI episodes. Patient satisfaction was high, with 97% satisfied and 80% ...

"I think this is a very important trial, just to bring some importance about patients' worries about being sexually active with urinary incontinence," says LeRoy Jones, MD. “There are a lot of social ...

Anktiva is the first drug to rescue T and NK cells, crucial for cancer cell eradication and memory generation. The "triangle offense" involves NK cells, CD8 killer T cells, and memory T cells, forming ...

Panelists explore challenges in identification of patients with intermediate-risk disease and emphasize importance of risk stratification to improve outcomes with regard to NMIBC.

“I would say both there could be an increase in MRI-guided [SBRT] and there may be increase in investigation into shrinking margins with CT-guided SBRT as well,” says Amar U. Kishan, MD. In this video ...

"Despite the fact that multiple new procedures have come to light, nothing has the same excellent outcomes as HoLEP," says Amy E. Krambeck, MD. In this video, Amy E. Krambeck, MD, discusses the key ...

All nine patients with stage III/IV ccRCC showed anti-tumor responses and remained disease-free three years post-vaccination. The vaccine induced durable T cell activation and immune responses against ...

Panelists discuss how for patients with BCG-unresponsive bladder cancer, treatment selection depends on key factors including tumor characteristics (carcinoma in situ vs papillary), patient fitness, ...